127 related articles for article (PubMed ID: 7617651)
1. Expression of tumor-associated glycoprotein 72 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.
Myers RB; Schlom J; Srivastava S; Grizzle WE
Mod Pathol; 1995 Apr; 8(3):260-5. PubMed ID: 7617651
[TBL] [Abstract][Full Text] [Related]
2. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia.
Jack GS; Brash AR; Olson SJ; Manning S; Coffey CS; Smith JA; Shappell SB
Hum Pathol; 2000 Sep; 31(9):1146-54. PubMed ID: 11014584
[TBL] [Abstract][Full Text] [Related]
3. Lewis Y antigen as detected by the monoclonal antibody BR96 is expressed strongly in prostatic adenocarcinoma.
Myers RB; Srivastava S; Grizzle WE
J Urol; 1995 May; 153(5):1572-4. PubMed ID: 7714977
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
5. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.
Myers RB; Srivastava S; Oelschlager DK; Grizzle WE
J Natl Cancer Inst; 1994 Aug; 86(15):1140-5. PubMed ID: 7913137
[TBL] [Abstract][Full Text] [Related]
6. Applications of monoclonal antibodies in clinical cytology as exemplified by studies with monoclonal antibody B72.3. The George N. Papanicolaou award lecture.
Johnston WW
Acta Cytol; 1987; 31(5):537-56. PubMed ID: 3314301
[TBL] [Abstract][Full Text] [Related]
7. Amphiregulin expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 93 cases.
Bostwick DG; Qian J; Maihle NJ
Prostate; 2004 Feb; 58(2):164-8. PubMed ID: 14716741
[TBL] [Abstract][Full Text] [Related]
8. Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma.
Iczkowski KA; Pantazis CG; McGregor DH; Wu Y; Tawfik OW
Cancer; 2002 Dec; 95(12):2487-93. PubMed ID: 12467061
[TBL] [Abstract][Full Text] [Related]
9. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.
Gomes IM; Arinto P; Lopes C; Santos CR; Maia CJ
Urol Oncol; 2014 Jan; 32(1):53.e23-9. PubMed ID: 24239460
[TBL] [Abstract][Full Text] [Related]
10. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
Zhao J; Epstein JI
Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862
[TBL] [Abstract][Full Text] [Related]
11. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
Tavora F; Epstein JI
Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
13. Expression of tumor-associated glycoprotein-72 (TAG-72) antigen in human prostatic adenocarcinomas.
Karan D; Johansson SL; Lin MF; Batra SK
Oncol Rep; 2001; 8(5):1123-6. PubMed ID: 11496328
[TBL] [Abstract][Full Text] [Related]
14. TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49.
Brenner PC; Rettig WJ; Sanz-Moncasi MP; Reuter V; Aprikian A; Old LJ; Fair WR; Garin-Chesa P
J Urol; 1995 May; 153(5):1575-9. PubMed ID: 7536270
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue.
Hobisch A; Rogatsch H; Hittmair A; Fuchs D; Bartsch G; Klocker H; Bartsch G; Culig Z
J Pathol; 2000 Jul; 191(3):239-44. PubMed ID: 10878544
[TBL] [Abstract][Full Text] [Related]
16. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
[TBL] [Abstract][Full Text] [Related]
17. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.
Uetsuki H; Tsunemori H; Taoka R; Haba R; Ishikawa M; Kakehi Y
J Urol; 2005 Aug; 174(2):514-8. PubMed ID: 16006883
[TBL] [Abstract][Full Text] [Related]
18. Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas.
Myers RB; Meredith RF; Schlom J; LoBuglio AF; Bueschen AJ; Wheeler RH; Stockard CR; Grizzle WE
J Urol; 1994 Jul; 152(1):243-6. PubMed ID: 8201675
[TBL] [Abstract][Full Text] [Related]
19. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study.
Sasor A; Wagrowska-Danilewicz M; Danilewicz M
Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901
[TBL] [Abstract][Full Text] [Related]
20. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
